US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ready Capital Corp

24.88

0.0000

Post-market: 24.880.00000.00%16:12 EST

Volume:78.00

Turnover:1.94K

Market Cap:4.09B

PE:- -

High:24.88

Open:24.88

Low:24.88

Close:24.88

52wk High:26.87

52wk Low:23.97

Shares:164.33M

Float Shares:164.33M

Volume Ratio:0.03

T/O Rate:0.00%

Dividend:1.44

Dividend Rate:5.78%

ROE:-13.30%

ROA:-2.87%

PB:2.46

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

Kura Oncology Reports Third Quarter 2025 Financial Results

Exelixis’s Strategic Positioning and Market Prospects Justify Buy Rating Amid RCC Treatment Dynamics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RCC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","market":"US","secType":"STK","nameCN":"Ready Capital Corp","latestPrice":24.88,"timestamp":1764968400000,"preClose":24.88,"halted":0,"volume":78,"hourTrading":{"tag":"盘后","latestPrice":24.88,"preClose":24.88,"latestTime":"16:12 EST","volume":4,"amount":99.5988,"timestamp":1764969123210},"delay":0,"floatShares":164327000,"shares":164327000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"12-05 16:00:00 EST","open":24.88,"high":24.88,"low":24.88,"amount":1942.9505,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":24.88,"dividendRate":0.057778,"postHourTrading":{"tag":"盘后","latestPrice":24.88,"preClose":24.88,"latestTime":"16:12 EST","volume":4,"amount":99.5988,"timestamp":1764969123210},"volumeRatio":0.028600760694432188},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","floatShares":164327000,"roa":"-2.87%","roe":"-13.30%","lyrEps":0,"volumeRatio":0.028600760694432188,"shares":164327000,"dividePrice":1.437515,"high":24.88,"amplitude":0,"preClose":24.88,"low":24.88,"week52Low":23.97,"pbRate":"2.46","psRate":"-38.15","week52High":26.87,"institutionHeld":0,"latestPrice":24.88,"eps":0,"divideRate":0.057778,"volume":78,"delay":0,"ttmEps":0,"open":24.88,"prevYearClose":24.42,"prevWeekClose":24.8,"prevMonthClose":24.8,"prevQuarterClose":24.95,"fiveDayClose":24.8,"twentyDayClose":24.81,"sixtyDayClose":24.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCC\",params:#limit:5,,,undefined,":[{"date":"2025-10-15","symbol":"RCC","amount":0.359375,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-15","defaultRemindTime":1760535000000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-30","payableDate":"2025-10-15","currency":"USD","dateTimestamp":1760500800000,"payDate":"2025-10-30"},{"date":"2025-07-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-15","defaultRemindTime":1752586200000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-07-15","currency":"USD","dateTimestamp":1752552000000,"payDate":"2025-07-30"},{"date":"2025-05-08","symbol":"RCC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"date":"2025-04-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-15","defaultRemindTime":1744723800000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-15","currency":"USD","dateTimestamp":1744689600000,"payDate":"2025-04-30"},{"market":"US","date":"2025-03-03","symbol":"RCC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCC\",market:\"US\",,,undefined,":[{"executeDate":"2021-04-14","recordDate":"2021-04-15","paymentDate":"2021-04-30","value":0.3194444,"currency":"USD"},{"executeDate":"2021-07-14","recordDate":"2021-07-15","paymentDate":"2021-07-30","value":0.359375,"currency":"USD"},{"executeDate":"2021-10-14","recordDate":"2021-10-15","paymentDate":"2021-10-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-01-13","recordDate":"2022-01-14","paymentDate":"2022-01-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-04-13","recordDate":"2022-04-14","paymentDate":"2022-04-30","value":0.359375,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RCC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.8571,"sell":0.1429,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.8571,"analysts":7,"updateTime":1741064400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589841767","title":"Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589841767","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589841767?lang=en_us&edition=fundamental","pubTime":"2025-12-06 11:11","pubTimestamp":1764990660,"startTime":"0","endTime":"0","summary":"Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mO","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201030/0/en/Toripalimab-Presents-Long-Term-Survival-Benefits-as-1st-line-Treatment-for-Advanced-Nasopharyngeal-Carcinoma-and-Esophageal-Squamous-Cell-Carcinoma-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","HCC","BK4157","IE0031619046.USD","IE00B7SZL793.SGD","BK4161","RCC","GP","OS","ORR","BK4149","IE00B19Z4B17.USD","LU0054578231.USD","IE00B66KJ199.SGD","LU0757428866.USD","BK4006","AEIS","LU1815336091.USD","PFS","BK4097","LU0053671581.USD","BK4195","ITT"],"gpt_icon":0},{"id":"2586299606","title":"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586299606","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586299606?lang=en_us&edition=fundamental","pubTime":"2025-11-27 08:00","pubTimestamp":1764201600,"startTime":"0","endTime":"0","summary":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov.  27, 2025  (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from severa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/27/3195434/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-2025-ESMO-Asia-Congress-and-the-2025-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0162691827.USD","S","BK4588","LU1244550494.USD","PD","LU1244550577.SGD","BK1588","LU2236285917.USD","LU2462157665.USD","BK4560","RCC","BK4534","BK4023","BK4097","AG","BK4516","LU2456880835.USD","BK4574","LU0130517989.USD","BK1587","LU1267930227.SGD","BK4504","00013","LU2286300806.USD","BK4561","LU2360032135.SGD","BK4559","LU0170899867.USD","LU0648001328.SGD","BK4539","BK4585","LU0130102774.USD","LU0128525689.USD","LU1244550221.USD","LU0980610538.SGD","LU0310800965.SGD","LU0477156953.USD","ASH","F","LU0320765646.SGD","LU2125154935.USD","BK4109","BK4555","IE00BSNM7G36.USD","LU0106831901.USD","BK4099","LU1201861249.SGD","BK4207","LU0072461881.USD","BK1191"],"gpt_icon":0},{"id":"2580780289","title":"Kura Oncology Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780289","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580780289?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:31","pubTimestamp":1762255860,"startTime":"0","endTime":"0","summary":"– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate zif","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180088/35186/en/Kura-Oncology-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4139","BK4109","KURA","RCC","LU2463526074.USD","ASH","BK4505"],"gpt_icon":0},{"id":"2578496817","title":"Exelixis’s Strategic Positioning and Market Prospects Justify Buy Rating Amid RCC Treatment Dynamics","url":"https://stock-news.laohu8.com/highlight/detail?id=2578496817","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578496817?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:55","pubTimestamp":1761659717,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh has maintained their bullish stance on EXEL stock, giving a Buy rating yesterday. Andy Hsieh has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/exelixiss-strategic-positioning-and-market-prospects-justify-buy-rating-amid-rcc-treatment-dynamics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/exelixiss-strategic-positioning-and-market-prospects-justify-buy-rating-amid-rcc-treatment-dynamics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXEL","RCC"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RCC\",params:#limit:6,delay:false,,,undefined,":[]}}